Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | CRYZ | Q08257 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclophosphamide Anhydrous SCHEMBL28088100 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL7304 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL14192809 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5328735 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL1285823 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL20542636 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4994883 | 0.98 | NPSR1 (0.96) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5802618 | 0.98 | NPSR1 (0.96) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL6071 | 0.98 | KDM4E (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5436000 | 0.98 | KDM4E (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 313011 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144239-A1 | Immune Cell-Engrafted Non-Human Animals and Non-Human Animal Models | LAPIX THERAPEUTICS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144870-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20260144874-A1 | COMPOSITIONS FOR TREATMENT OF AUTOIMMUNE DISEASES | NKARTA, INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4746898-A2 | IDENTIFICATION OF SEQUENCE VARIANTS OF THE ERVMER34-1 SEQUENCE FAMILY AND USE IN ANTI-CANCER THERAPIES | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746899-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH TROP-2 TARGETING ADC | Iovance Biotherapeutics, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3727367-B1 | VITAMIN K2 COMPOSITIONS FOR USE IN THE TREATMENT OF DRUG INDUCED NEUROPATHY | SYNERGIA LIFE SCIENCES PVT LTD (IN) | 2026-05-27 | — | — | EP | claimed |
| EP-4749286-A2 | METHOD OF ASSESSING RISK OF PML | Biogen MA Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| WO-1981000256-A1 | (N-PHOSPHONACETYL-L-ASPARTATO)(1,2-DIAMINOCYCLOHEXANE)-PLATINUM(II)OR ALKALI METAL SALT | US COMMERCE (US) | 1981-02-05 | — | — | WO | claimed |
| US-4220660-A | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents | Asta-werke Aktiengesellschaft, Chemische Farik (DE) | 1980-09-02 | — | — | US | claimed |
| US-4218471-A | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents | ASTA-WERKE AKTIENGESELLSCHAFT CHEMISCHE FABRIK (DE) | 1980-08-19 | — | — | US | claimed |
| US-4206207-A | Use of 4-carboxy-phthalato(1,2-diaminocyclohexane)-platinum (II) and alkali metal salts thereof with cyclophosphamide in alleviating L1210 murine leukemia | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-06-03 | — | — | US | claimed |
| US-4206208-A | Use of 4-carboxy-phthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof with cyclophosphamide and 5-fluorouracil in alleviating L1210 murine leukemia | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-06-03 | — | — | US | claimed |
| EP-0010964-A1 | Ravidomycin, process of preparation and pharmaceutical compositions containing same | AYERST, MCKENNA AND HARRISON INC. (CA) | 1980-05-14 | — | — | EP | claimed |
| US-4202890-A | 4-Carboxy-phthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof with cyclophosphamide and hydroxyurea in alleviating L1210 murine leukemia | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH, EDUCATION AND WELFARE (US) | 1980-05-13 | — | — | US | claimed |
| EP-0007206-A1 | Phenethanolamines, their formulations, preparation and use | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | claimed |
| US-4106488-A | Cancer treatment method | GORDON, DAVID, SKOKIE, ILLINOIS | 1978-08-15 | — | — | US | claimed |
| US-3987166-A | TREATMENT OF TUMORS WITH GLUCAN COMPOSITIONS IN MICE AND RATS | KAKEN KAGAKU KABUSHIKI KAISHA (JA) | 1976-10-19 | — | — | US | claimed |